Press Release • Press Release • Press Release • Press Release • Press Release

Vivimed

Vivimed

For Immediate Release

September 21, 2015

Vivimed announces satisfactory outcome of USFDA inspection

With this outcome at its API facility in Spain, all of the Company's manufacturing plants focussed on the regulated markets have been inspected with a favourable outcome, over the last one year

Hyderabad, India, September 21, 2015 – Vivimed Labs Limited ("Vivimed" or the Company), a niche Specialty Chemicals and Pharmaceuticals company, announced today that its API manufacturing facility located in Lliçà de Vall, Spain has had a favourable outcome post its US Food and Drug Administration (USFDA) inspection. The audit was conducted during the second week of September and concluded on 18 September, 2015.

On completion of the inspection the USFDA inspectors concluded that the facility, its systems and practices comply with USFDA requirements with no observations reported on the form 483.

During the last one year, Vivimed has had a satisfactory outcome on the regulatory compliance front with all four of its USFDA approved manufacturing plants including Sant Celoni, Spain (May 2015), Alathur, India (February 2015), Cuernavaca, Mexico (September 2014) and now Lliçà de Vall, Spain.

Commenting on the development, **Mr. Santosh Varalwar, Managing Director** and **CEO** said:

"I am happy to announce that our team has been able to achieve a satisfactory outcome from the recent USFDA inspection for one of our API facilities in Spain. This is in line with the Group's constant focus on maintaining high levels of regulatory compliance, which is a key differentiator in today's evolving regulatory landscape, in the global generic pharmaceuticals market. We believe this development and the similar success achieved by our teams across our other three manufacturing facilities is good news for our business, valued customers and gives us an opportunity to further fortify our presence in the selected markets."

Analyst and Investor Enquiries

Amarjit Bhatia, CFO
Vivimed Labs Limited
+91 40 2717 6005
amarjit.bhatia@vivimedlabs.com

Saket Somani
Churchgate Partners
+91 22 6169 5988
Vivimed@churchgatepartnersindia.com

For further information on Vivimed, visit www.vivimedlabs.com

Safe Harbour

This release contains "forward looking statements" including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Vivimed's future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macroeconomic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Vivimed undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.

Vivimed Labs Ltd (Corporate Office)
CIN : L02411KA1988PLC009465
Veernag Towers, Habsiguda, Hyderabad, Telangana - 500 007, India
T +91 (0) 40-2717 6005/6 F +91 (0) 40-2715 0599
contact@vivimedlabs.com www.vivimedlabs.com

For VIVIMED LABS LTD.
Company Secretary